92.9 USD
+0.45 (+0.49%)
92.9 USD
0 (0%)
Overall AZN gets a fundamental rating of 6 out of 10. We evaluated AZN against 192 industry peers in the Pharmaceuticals industry. While AZN has a great profitability rating, there are some minor concerns on its financial health. AZN is not valued too expensively and it also shows a decent growth rate. Finally AZN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year AZN was profitable.
AZN had a positive operating cash flow in the past year.
AZN had positive earnings in each of the past 5 years.
Each year in the past 5 years AZN had a positive operating cash flow.
1.2 Ratios
The Return On Assets of AZN (8.21%) is better than 89.58% of its industry peers.
With an excellent Return On Equity value of 20.48%, AZN belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
With an excellent Return On Invested Capital value of 14.42%, AZN belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 12.85%.
The 3 year average ROIC (11.62%) for AZN is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
Looking at the Profit Margin, with a value of 16.17%, AZN belongs to the top of the industry, outperforming 88.54% of the companies in the same industry.
AZN's Profit Margin has improved in the last couple of years.
The Operating Margin of AZN (24.34%) is better than 91.15% of its industry peers.
In the last couple of years the Operating Margin of AZN has grown nicely.
AZN's Gross Margin of 81.90% is amongst the best of the industry. AZN outperforms 85.42% of its industry peers.
AZN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AZN is still creating some value.
Compared to 1 year ago, AZN has about the same amount of shares outstanding.
Compared to 5 years ago, AZN has more shares outstanding
The debt/assets ratio for AZN is higher compared to a year ago.
2.2 Solvency
AZN has an Altman-Z score of 3.52. This indicates that AZN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.52, AZN is in the better half of the industry, outperforming 68.23% of the companies in the same industry.
The Debt to FCF ratio of AZN is 3.41, which is a good value as it means it would take AZN, 3.41 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.41, AZN belongs to the best of the industry, outperforming 86.98% of the companies in the same industry.
A Debt/Equity ratio of 0.61 indicates that AZN is somewhat dependend on debt financing.
AZN has a worse Debt to Equity ratio (0.61) than 67.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.52 |
ROIC/WACC1.59
WACC9.05%
2.3 Liquidity
A Current Ratio of 0.88 indicates that AZN may have some problems paying its short term obligations.
AZN has a Current ratio of 0.88. This is amonst the worse of the industry: AZN underperforms 88.02% of its industry peers.
A Quick Ratio of 0.69 indicates that AZN may have some problems paying its short term obligations.
AZN's Quick ratio of 0.69 is on the low side compared to the rest of the industry. AZN is outperformed by 86.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.61% over the past year.
AZN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
Looking at the last year, AZN shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
AZN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
The Earnings Per Share is expected to grow by 12.45% on average over the next years. This is quite good.
Based on estimates for the next years, AZN will show a small growth in Revenue. The Revenue will grow by 7.17% on average per year.
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.20 indicates a rather expensive valuation of AZN.
AZN's Price/Earnings ratio is rather cheap when compared to the industry. AZN is cheaper than 81.25% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.57, AZN is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 17.74, the valuation of AZN can be described as rather expensive.
AZN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AZN is cheaper than 79.17% of the companies in the same industry.
AZN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.2 | ||
| Fwd PE | 17.74 |
4.2 Price Multiples
AZN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AZN is cheaper than 81.77% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AZN is valued cheaper than 81.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.11 | ||
| EV/EBITDA | 15 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AZN has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as AZN's earnings are expected to grow with 12.20% in the coming years.
PEG (NY)1.69
PEG (5Y)1.09
EPS Next 2Y12.55%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.63%, AZN has a reasonable but not impressive dividend return.
AZN's Dividend Yield is rather good when compared to the industry average which is at 0.61. AZN pays more dividend than 92.19% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.00, AZN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
5.2 History
The dividend of AZN has a limited annual growth rate of 1.40%.
AZN has paid a dividend for at least 10 years, which is a reliable track record.
AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
5.3 Sustainability
52.89% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
AZN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP52.89%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
92.9
+0.45 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner Change11.46%
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap288.04B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target97.35 (4.79%)
Short Float %0.31%
Short Ratio1.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)4.58%
PT rev (3m)4.64%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)-1.95%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)0.57%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.2 | ||
| Fwd PE | 17.74 | ||
| P/S | 4.96 | ||
| P/FCF | 30.11 | ||
| P/OCF | 19.03 | ||
| P/B | 6.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15 |
EPS(TTM)4.6
EY4.95%
EPS(NY)5.24
Fwd EY5.64%
FCF(TTM)3.09
FCFY3.32%
OCF(TTM)4.88
OCFY5.26%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)1.69
PEG (5Y)1.09
Graham Number39.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 3.52 |
F-Score7
WACC9.05%
ROIC/WACC1.59
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
What is the fundamental rating for AZN stock?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status of ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
Can you provide the profitability details for ASTRAZENECA PLC-SPONS ADR?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for AZN stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 20.2 and the Price/Book (PB) ratio is 6.28.
How financially healthy is ASTRAZENECA PLC-SPONS ADR?
The financial health rating of ASTRAZENECA PLC-SPONS ADR (AZN) is 4 / 10.